AbbVie Inc. (ABBV)
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.
2 Super Smart Dividend Stocks to Buy With $10,000 Right Now
Many dividend stocks have recently taken a back seat to growth stocks. However, dividend stocks offer several advantages to investors.
AbbVie says FDA approves Skyrizi for ulcerative colitis
Drug maker AbbVie Inc. on Tuesday said the Food and Drug Administration had approved its drug Skyrizi for adults with moderate to severe forms of ulcerative colitis, broadening the company's arsenal of treatments for bowel disorders.
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, AbbVie (ABBV) stood at $171.36, denoting a +0.99% change from the preceding trading day.
AbbVie: 5 Reasons That Make A Buy Case
AbbVie's weak stock price performance in the past quarter is in no way an indication of the progress it has made in recent months. Turnaround in revenue growth following Humira's patent expiration is now evident and recent acquisitions could bolster growth further. EPS trends have improved too, while a stable operating income is also encouraging.
2 Dividend Stocks That Could Pay You for Life
AbbVie's strength lies in its ability to innovate. Visa's success is tied to an ongoing long-term trend.
AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.
The Dividend Defenders: 3 Stocks That Will Protect and Grow Your Wealth Dividend Stocks
With the markets trading at all-time highs, it's natural to want to protect your gains by turning to a more defensive strategy. As we've seen throughout history, when the markets go up, they tend to pull back to retest key averages and demand levels.
AbbVie inks immune disorder drug licensing deal with China's FutureGen
U.S. drugmaker AbbVie will develop and commercialize an experimental treatment for inflammatory bowel disease (IBD) from China's FutureGen Biopharmaceutical under a licensing agreement, the companies said on Thursday.
AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
AbbVie, Inc. (NYSE:ABBV ) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 10:00 AM ET Company Participants Robert Michael - President & COO Jeffrey Stewart - EVP & Chief Commercial Officer Roopal Thakkar - SVP & Chief Medical Officer, Global Therapeutics Scott Reents - EVP & CFO Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Welcome everybody. Glad that you can join us.
Blue-Chip Bonanzas: 3 Industry Leaders Trading at Unbelievable Discounts
When it comes to targeting discounted ideas in the equities sector, undervalued blue-chip stocks offer some of the most compelling prospects. First and foremost, blue chips earn the status through decades of business and earnings expansion.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
